Drucker J
Department of Public Health, Centre Hospitalier Universitaire, Tours, France.
Pediatr Infect Dis J. 1991 Dec;10(12):967-9. doi: 10.1097/00006454-199112000-00028.
In France, infants are immunized against paralytic poliomyelitis with enhanced-potency inactivated poliovirus vaccine (eIPV) combined with the diphtheria-tetanus-pertussis vaccine (DTP). Ninety-five percent of all infants in France have received four doses of DTP-eIPV by 24 months of age. No cases of vaccine-associated paralysis, among either recipients or those in contact with recipients, have been reported since 1983, when eIPV became the vaccine of choice. Only three wild indigenous cases have been reported among unvaccinated children in 1988 and 1989, with no cases reported in 1990. Although paralytic poliomyelitis has been virtually eliminated in France, vaccination programs as well as active surveillance of the community and environment for poliovirus circulation should be reinforced to reach the goal of wild poliovirus eradication.
在法国，婴儿接种增强效力的灭活脊髓灰质炎病毒疫苗（eIPV）与白喉 - 破伤风 - 百日咳疫苗（DTP）联合制成的疫苗，以预防麻痹性脊髓灰质炎。法国95%的婴儿在24个月大时已接种四剂DTP - eIPV。自1983年eIPV成为首选疫苗以来，未报告过接种者或与接种者接触者发生疫苗相关麻痹病例。1988年和1989年，未接种疫苗的儿童中仅报告了3例本土野生病例，1990年无病例报告。尽管法国实际上已消除麻痹性脊髓灰质炎，但仍应加强疫苗接种计划以及对社区和环境中脊髓灰质炎病毒传播的主动监测，以实现根除野生脊髓灰质炎病毒的目标。
